NUVISAN and Bayer Create New Research Unit in Berlin
NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. NUVISAN is an international service provider for clinical studies, laboratory services and contract manufacturing (CRO / CDMO) with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a new research entity to be established by NUVISAN in Berlin and confirms the longstanding cooperation between the two companies.
“With NUVISAN we have found an excellent partner with a clear plan to build up a strong full- fledged research unit in Berlin together with our dedicated team of scientists,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development. “NUVISAN shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists”.
The partnered Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research center comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics and Investigational Toxicology.
"With these new drug discovery capabilities and capacities in the field of drug discovery, we do not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology and continuously expand the range of services," says Dr. Dietrich Bruchmann, CEO and managing partner of NUVISAN. “The acquisition of the research unit and our commitment to the location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow the combined businesses to significantly accelerate the drug development process from discovery to clinical trials. There is hardly any overlap in our range of services, so that we can immediately benefit from a variety of synergies and operational advantages through the new research center.”
NUVISAN and Bayer will cooperate closely in the coming years to build the new research center. The transaction is expected to close mid of 2020. Financial terms were not disclosed.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
